Related Experiment Video

Updated: Aug 6, 2026

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

New Treatment Strategy and Future Research Direction for BRAF-Mutated Cancer

Masanobu Takahashi1,2, Sakura Hiraide Taniguchi2, Yuya Yoshida2

  • 1Department of Clinical Oncology, Faculty of Medicine, Yamagata University, Yamagata, Japan.

Cancer Science
|July 23, 2026
PubMed

Insights

BRAF-targeted therapies show promise for various cancers, including melanoma and lung cancer. Overcoming resistance to these treatments is crucial for improving patient outcomes in BRAF-mutated malignancies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • BRAF oncogene mutations, particularly BRAFV600E, drive cancer cell growth and survival via the MAPK pathway.
  • Targeted therapies, including BRAF and MEK inhibitors, have been developed for BRAF-mutated cancers.
  • Tumor-agnostic approval for BRAF inhibitor plus MEK inhibitor therapy (excluding colorectal cancer) occurred in 2022.

Purpose of the Study:

  • To review the clinical development of BRAF-targeted therapies.
  • To discuss mechanisms of intrinsic and acquired resistance to BRAF-targeted therapies.
  • To explore novel treatment strategies for BRAF-mutated cancers.

Main Methods:

  • Review of clinical trial data and scientific literature on BRAF-targeted therapies.
  • Analysis of resistance mechanisms in BRAF-mutated cancers.
  • Discussion of emerging treatment approaches and combinations.

Main Results:

  • BRAF inhibitors, alone or in combination with MEK inhibitors or anti-EGFR antibodies, are established treatments for several cancers.
  • Resistance to BRAF-targeted therapies remains a significant clinical challenge.
  • Combination therapies, including chemotherapy, are being investigated for colorectal cancer.

Conclusions:

  • BRAF-targeted therapies have advanced cancer treatment, but overcoming resistance is essential.
  • Further research into resistance mechanisms and novel therapeutic strategies is needed.
  • Personalized treatment approaches are key for managing BRAF-mutated cancers effectively.
Keywords:
BRAFBRAF inhibitorBRAF‐mutated cancerMEK inhibitoranti‐EGFR antibody

More Related Videos

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma08:18

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma

Published on: September 8, 2021

A 3D Organotypic Melanoma Spheroid Skin Model08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.